Detalles de la búsqueda
1.
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Cancer Immunol Immunother
; 70(5): 1255-1262, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33130956
2.
Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
BJU Int
; 120(5B): E45-E51, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987524
3.
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial.
Blood Adv
; 4(23): 5951-5957, 2020 12 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33275769
4.
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
J Thorac Oncol
; 14(1): 115-123, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30267838
5.
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.
Radiother Oncol
; 126(2): 257-262, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29103826
6.
Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
J Clin Oncol
; 34(5): 495-500, 2016 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26712227
7.
Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10.
J Clin Oncol
; 33(35): 4158-66, 2015 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26527774
Resultados
1 -
7
de 7
1
Próxima >
>>